Value-based drug management is an approach that focuses on reducing prescription drug costs by targeting waste, high-cost specialty claims, and excessive profiteering, rather than simply chasing discounts and rebates. For self-funded health plans, it represents a fundamental shift in how prescription benefit costs are managed and where attention is directed.
Why the Old Approach to Drug Cost Management No Longer Works
For decades, prescription drug cost management has centered on brand and generic medications, negotiating discounts, pursuing rebates, and managing volume. That focus made sense when those drugs drove the majority of the plan. It no longer reflects where the real cost pressure is coming from.
Brand and generic medications make up almost 99% of total prescriptions, and they have long been the primary focus of most cost reduction efforts. But specialty drugs, including new cell and gene therapies, have fundamentally changed the equation. What used to represent roughly 10% of drug benefit spend now accounts for over 50%. And a comparable amount of high-cost specialty drug spend is hidden inside medical benefit programs, making it even harder to see and manage.
Continuing to optimize for rebates on high-volume, lower-cost drugs while the specialty drug line grows unchecked means leaving the largest cost driver largely unaddressed.
What Value-Based Drug Management Actually Means
Value-based drug management shifts focus away from volume-driven sourcing and toward clinical accountability for the highest-cost claims. Instead of optimizing for rebates, it asks harder questions: Is this medication clinically appropriate? Is the patient getting the right drug, at the right dose, at the right time, and at the best price possible?
For high-cost specialty claimants, that kind of clinical oversight is essential. The medical needs of these members are fundamentally different from the rest of the plan population, and without careful management, millions of dollars can quickly vanish. A thoughtful, clinical sourcing approach for specialty claims, one that involves interacting directly with providers and patients, is what separates value-based management from traditional cost-cutting tactics.
Importantly, this approach doesn’t ignore volume-driven sourcing. It addresses the entire drug spend from top to bottom, starting with the highest-impact opportunities first.
Specialty Drug Impact Is Bigger Than Most Plans Realize
Specialty drugs now represent the single largest driver of drug and medical benefit costs for self-funded plans and the pipeline is only growing. The pharmaceutical industry’s development pipeline is heavily concentrated in high-cost specialty therapies, including cell and gene treatments that carry extraordinary price tags per patient.
GLP-1 receptor agonists are a timely example of how quickly specialty drug costs can reshape a plan’s financial picture. Initially approved for type 2 diabetes, their expanded use for obesity and cardiovascular risk management has driven rapid adoption and significant recurring cost for employer plans.
Real-world data shows that outcomes diverge meaningfully from clinical trial results when structured lifestyle support isn’t part of the picture, raising important questions about whether broad coverage without clinical guardrails actually delivers value proportionate to the spend. For plan sponsors, GLP-1s illustrate exactly why clinical oversight and evidence-based benefit design matter more than simply providing access.
This pattern, a high-cost therapy generating significant spend without a disciplined framework for deployment, is precisely what value-based drug management is designed to address.
What to Look for in a Prescription Drug Benefits Consultant
Employers evaluating consulting support for drug cost management should look for firms that bring both clinical expertise and analytical independence to the work. Specifically:
- Clinical depth — pharmacists and consultants who understand the therapeutic landscape, not just the contracting mechanics
- Conflict-free structure — no financial relationships with PBMs, specialty pharmacies, or drug manufacturers that could influence recommendations
- Specialty focus — demonstrated experience managing high-cost outlier claims, not just standard formulary optimization
- Integrated oversight — the ability to identify and manage specialty drug spend buried in medical benefits, not just the pharmacy line
- Transparent reporting — ongoing monitoring of drug spend trends throughout the year, not just annual reviews at renewal
What Chelko Consulting Group Does Differently
Chelko’s Value-Based Drug Management approach draws on deep expertise in both prescription drug and medical benefits, applying a custom combination of proven strategies to reduce cost without adversely impacting member experience or quality of care.
Rather than chasing discounts and rebates, the focus is on removing waste and excessive profiteering from plans while helping members more affordably access the medications they need. Clinical reviews and recommendations are conducted at both the plan and claimant levels, covering Prior Authorization Management, Site of Care management, and Cell and Gene Therapy Management, the kinds of high-complexity interventions that generate the most meaningful savings.
The results speak for themselves: clients have reduced overall specialty drug spend by 30%, with savings of hundreds of thousands, and in some cases millions, of dollars on specific high-cost claimants. All delivered through a conflict-free model that never accepts overrides or contingent compensation from vendors, and backed by named fiduciary accountability that is unique in the industry.
Learn More About Our Value-Based Drug Management Approach →
Frequently Asked Questions
What is value-based drug management for self-funded health plans? Value-based drug management is an approach that focuses on clinical accountability and targeted oversight of high-cost specialty claims, rather than volume-based discounts and rebates — to reduce prescription drug costs while maintaining quality of care for plan members.
Why are specialty drugs the biggest cost driver for employer health plans? Specialty drugs, including cell and gene therapies, now account for over 50% of drug benefit spend for many employer plans — up from roughly 10% historically. Their clinical complexity and high unit costs make them the primary target for effective drug cost management.
Why isn’t chasing rebates enough to control drug costs? They are poorly suited for managing specialty claims, where clinical oversight and sourcing strategy have far more impact than rebate negotiations.
How does conflict-free consulting improve drug cost management outcomes? When a consultant has no financial relationships with PBMs, specialty pharmacies, or drug manufacturers, recommendations are based purely on clinical and financial merit. That independence is especially important in specialty drug management, where financial incentives in the supply chain are significant.